Introduction

Serum amyloid A protein (SAA), also known as serum amyloid protein A, is a 600-nucleotide long (1) and 122 amino acids protein and the encoding gene is located on chromosome 11p15.1 (2). In the human, SAA gene family contains the highly homologue SAA1, SAA2, SAA3 and SAA4 (3). SAA is an acute phase reactive protein as well as a high-density lipoprotein (HDL)-related protein (4,5). Meanwhile, SAA is expressed principally in hepar and extrahepatic cells or tissues such as epithelial cells, lymphocytes, and cancer cells (6) while occurring trauma,
inflammation, infection, and oncogenesis (6,7).

SAA modulates cell adhesion, migration (8) in inflammation by inducing cytokines [IL-8 (9), G-CSF (10), etc.] expression and plays an important role in metabolism and transport of HDL and cholesterol (11). In addition, in the oncogenesis and tumor progression of various malignancies, chronic and lasting inflammation was considered as a crucial factor (12-15). But the function of SAA in oncogenesis still remains not clearly explained, and published studies suggest that SAA could become a biomarker to evaluate the growth of tumor and host response activity (16).

Following the explosive growth of knowledge of cancer biology, prognostic biomarker searching has been the most important fields of clinical oncology. A growing number of publications stated that chronic inflammation plays a prognostic role in many different cancers (17,18) and SAA status has been suggested as a prognostic biomarker for several tumors, such as renal cell carcinoma (RCC) (19), breast carcinoma (20), melanoma (21), lung cancer (22) and gastric carcinoma (23). The aim of this systematic review and meta-analysis was to clearly and comprehensively understand the prognostic value of SAA in different cancers with a standardized meta-analysis technique.

We present the following article in accordance with the PRISMA reporting checklist (available at http://dx.doi.org/10.21037/tcr-20-3417).

<table>
<thead>
<tr>
<th>Study eligibility criteria</th>
<th>Detail</th>
</tr>
</thead>
<tbody>
<tr>
<td>SAA definition</td>
<td>Serum amyloid a protein as defined by each study (no restriction regarding laboratory method, immunity method)</td>
</tr>
<tr>
<td>Outcome measure</td>
<td>Overall survival</td>
</tr>
<tr>
<td>Study design</td>
<td>Prospective or retrospective cohort studies</td>
</tr>
<tr>
<td>Patient age</td>
<td>Any</td>
</tr>
<tr>
<td>Anatomical site</td>
<td>Any</td>
</tr>
<tr>
<td>Study tissue</td>
<td>Any</td>
</tr>
<tr>
<td>Stage</td>
<td>Any</td>
</tr>
<tr>
<td>Therapy</td>
<td>Any</td>
</tr>
<tr>
<td>Length of follow-up</td>
<td>Any</td>
</tr>
</tbody>
</table>

**Methods**

**Search strategy and study eligibility**

Published studies were comprehensively searched on two independent databases PubMed and EBSCO till January 2020 using the MeSH words: “serum amyloid A protein” AND “Neoplasms”. SAA levels were determined by each author of the studies with immunity method value. Overall survival (OS), which is defined as the length of time that patients were still alive from initial cancer diagnosis, was the primary outcome. Prospective cohort studies and retrospective ones were both included. Articles were ruled out following the criteria: (I) non-abstract or non-English article; (II) case reports or review articles; (III) duplicate ones. The other respects of the studies like patient ethnicity, type and stage of tumor, length of follow up, and therapeutic schedule was not restricted (study eligibility criteria outlined in Table 1).

**Publication identification and data extraction**

To identify the eligibility of the studies, every publication was examined by two authors independently according to Meta-analysis Of Observational Studies in Epidemiology (MOOSE) guideline (24). To exclude the unrelated articles, the titles and abstracts of each study were read carefully with a unified standard. The remaining relevant studies were deeply examined to check their relevance. We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines (25) to present the flow chart of study identification in Figure 1.

Two reviewers used the Newcastle-Ottawa Quality Assessment Scales to conduct the quality assessment independently for each study. And all differences between the two reviewers’ assessment were solved by consensus.
Figure 1 Study identification flowchart. Using standardized protocol for a comprehensive search through two electronic databases, a total of 10 studies were included in this review for qualitative or quantitative analysis.

**Statistical analysis**

We used Review Manager 5 to conduct the statistical analysis. The patients were divided into two constitutive groups according to SAA levels (SAA-high, SAA-low) by each study. Heterogeneity of clinical factors and methodological sources between studies were taken into consideration to assess whether it is appropriate to complete such a statistical synthesis. We calculated the heterogeneity using Q test, and measured the discordance of pooled OR by $I^2$ statistics (26). For this meta-analysis, we defined an $I^2$ statistic of <50% as an indication of acceptable heterogeneity. Funnel plots were drew to evaluate the publication bias.

For the meta-analysis, OS was defined as the primary outcome. We used the weighted average of ORs to get a summary of the relationship between OS and SAA expression, which can partially correct the variance of OR in each publication. Mantel-Haenszel Fixed-effects (27) model was used to complete the synthesis when $P<0.1$, $I^2<50\%$. In order to show the result of synthesis more clearly, forest plots presenting ORs of each study and pooled OR were completed. In the forest plots, the horizontal line segments indicated 95% confidence intervals (CIs), and the box in the middle of each line segment represented OR of each study. The vertical line was the reference line representing OR =1.0. At the bottom of the forest plots, the diamond represented the pooled OR, and the width represented the CIs. In order to evaluate the effect of cancer type of the result, subgroup analyses (RCC, lung cancer, digestive cancer, other or mixed) were conducted.

**Results**

**Eligible studies**

The 635 initially identified records were searched from two database (PubMed and EBSCO) with the MeSH words: “serum amyloid A protein” AND “Neoplasms” (flow chart
of study identification summarized in Figure 1). Then, 424 records were excluded for the reason of duplication, non-English and non-abstract. While conducting the initial title/abstract screen, we excluded 111 publications just because they were reviewed, case report, animal study or basic research; 100 studies remained for full-text inspection after title/abstract screening. The remained 100 records were carefully assessed for the eligible studies (Figure 1). During this procedure, 90 full-text articles were excluded for unavailable data or unrelated to the main topic (SAA, cancer and survival) and ten publications (21,28-36), published from 1986 to 2020, were qualified for the meta-analysis for the success to extract the necessary data.

Study characteristics

The characteristics of these ten publications were presented in Table 2. The total included patient number of all the publications was 1496, ranging from 58 to 379 per study (median =150). Four studies assessed RCC (21,28,30,36), two evaluated lung cancer (29,31), and one each assessed melanoma (21), esophageal carcinoma (33), gastric cancer (34), and different cancer (35). Almost all studies included different disease stages except one study not reported such relevant information. However, one study (32) examined only stage IIb or IIIa cancers, one (31) examined only stage I and II cancers, and one (28) examined only stage IV cancers.

Heterogeneity in SAA definition

The lab methods extracted from each included studies were presented in Table 2. Different lab methods were used for evaluating the SAA status, including two studies (32,36) used ELISA, two (31,34) LATI (latex agglutination turbid metric immunoassay), two (21,29) immunohistochemistry assay, one (28) conventional antibody-directed enumeration assays, one (35) used radioimmunoassay, one (33) polyclonal antibody and another one (30) was not reported. Different method and the staining score decided the different cutoff for elevated SAA status in each study. The total mean percentage of elevated SAA status patients was 45.3%. Melanoma and ESCC showed the highest percentage (far over 50%) of elevated SAA among the patients. The percentage of SAA overexpression in lung, gastric and renal cancer ranged 17.25% to 54.3%. Significant statistical heterogeneity was absent in 1-year survival (Q=14.94, I²=46%) (Figure 3), but present in 5-year survival (Q=24.83, I²=80%) (Figure 4).

Meta-analysis

Total OS

The combined analysis for the included ten studies showed that SAA status had a strong correlation with a shorter OS (1-year survival OR for death =5.07, 95% CI, 3.71–6.94, P<0.00001) (Figure 2), while no study indicated that SAA was correlated with a longer OS. We can also draw a similar conclusion for the 3-year OS (OR for death =4.21, 95% CI, 3.18 to 5.56, P<0.00001) (Figure 3) and 5-year OS (OR for death =5.69, 95% CI, 2.66–12.18, P<0.00001) (Figure 4).

OS for different cancers

In renal carcinoma (21,28,30,36), a high SAA status showed an unfavorable OS (OR for death at 1 year =4.76, 95% CI, 3.00–7.56; OR for death at 3 years = 4.89, 95% CI, 3.06–7.81; OR for death at 5 years =6.82, 95% CI, 2.63–17.68) (Figures 2-4). The two studies of digestive carcinoma (33,34) indicated that elevated SAA status correlated with a worse OS than that in RCC (OR for death at 1 years =12.99, 95% CI, 2.43–69.61, P<0.0001; OR for death at 3 years =9.15, 95% CI, 4.88–15.26, P<0.00001; OR for death at 5 years =8.63, 95% CI, 4.88–15.26, P<0.00001) (Figures 2-4). However, there was no statistical difference between digestive and non-digestive cancers. High status of SAA reported in another two studies of lung cancer was also associated with an unfavorable 1-year OS (OR for death =6.81, 95% CI, 2.21–20.92) (Figure 2).

Publication bias

Publication bias analysis of the ten studies were presented as funnel plots (Figure 5) and the results indicate negligible publication bias.

Discussion

A systematic review was carried out to evaluate the effect of SAA status on OS of patients with different kind of tumors. This meta-analysis showed a remarkable role of SAA in diverse cancer prognosis as well as in the subgroup of RCC, lung cancer and digestive carcinoma. No matter in early and locally advanced diseases (stages I–III) or in metastasis carcinoma (stage IV), our analysis showed an essential effect. Therefore, SAA could be included as one of the prognostic biomarker factors for cancers especially for RCC.
Table 2 Summary of included study characteristics

<table>
<thead>
<tr>
<th>Study</th>
<th>Study characteristics</th>
<th>Patient population</th>
<th>SAA assessment</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Findeisen P, et al. (21)</td>
<td>2009 Germany 379 Melanoma I-IV 208, 54.9% 54.7 (6.8–87.8) Immunonephelometric assay Low/high SAA &gt;10 mg/L 203, 53.6% 8 OS</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vermaat JS, et al. (I) (28)</td>
<td>2012 The Netherlands 114 mRCC IV 76, 67% 60 (49.9–70.1) Conventional antibody-directed enumeration assays Low/high SAA &gt;71 ng/mL 52, 45.6% 8 PFS, OS</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vermaat JS, et al. (II) (28)</td>
<td>2012 The Netherlands 151 mRCC IV 107, 71% 60.2 (50.1–70.3) Conventional antibody-directed enumeration assays Low/high SAA &gt;72 ng/mL 82, 54.3% PFS, OS</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Paret C, et al. (29)</td>
<td>2010 Germany 87 RCC NR NR NR Immunohistochemistry assay Negative/positive NR 15, 17.2% 7 OS</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Liu YS, et al. (30)</td>
<td>2012 China 106 Lung cancer IIb, IIIa NR NR [41–73] NR Low/high SAA &gt;17.05 56, 52.8% 7 OS, RFS</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wang JY, et al. (33)</td>
<td>2012 China 165 Esophageal squamous cell carcinoma I-IV 129, 78.2% 58.5 [40–70] Poly-clonal antibody Non-elevated/ elevated SAA &gt;8.0 mg/L 91, 55.2% 7 OS</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kwon HC, et al. (34)</td>
<td>2012 South Korea 115 Gastric cancer I-IV 68, 59.1% NR Latex agglutination turbidoimmunometric assays Low/high SAA &gt;4.2 mg/mL 57, 49.6% 8 DFS, OS</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Biran H, et al. (35)</td>
<td>1986 Israel 151 Cancer I-IV 48, 31.8% NR Radioimmunoassay Low/high SAA &gt;10 µg/mL 39, 25.8% 5 OS</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kimura M, et al. (31)</td>
<td>2001 Japan 72 RCC I-II NR 60.4 [34–81] Latex agglutination turbidometric immunoassay Normal/ elevated SAA &gt;8 mg/L 38, 52.8% 6 OS</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ramankulov A, et al. (36)</td>
<td>2008 Germany 98 RCC I-IV 66, 67.3% 60.0 [55–65] ELISA Low/high SAA &gt;27.7 mg/L 30, 30.6% 8 OS</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wang YS, et al. (32)</td>
<td>2013 Taiwan 58 Lung cancer I-IV 42, 72.4% 53.4% &lt;70 years ELISA Low/high SAA &gt;670 µg/mL 15, 25.9% 8 OS</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

mRCC, metastatic renal cell carcinoma; RCC, renal cell carcinoma; SAA, serum amyloid A protein; PFS, progression-free survival; OS, overall survival.
and digestive carcinoma. And should be selected with or for a further prospective study with our previous results CD166 and CD133 expressions.

Plenty of prognostic factors for different cancers existed in current references, such as breast cancer (37,38), bladder cancer (39,40), RCC (41), colorectal cancer (42), lung cancer and so on. The researchers have proved some clinical prognostic factors, mainly tumor staging and performance status (PS) (43). However, some clinical prognostic factors are not homogeneous, so that clinical oncologists cannot easily predict the survival for individual patients, such as tumor staging. Consequently, meta-analyses to evaluate the prognostic value of a new biological marker are urgent needed to solve the limitation statistical power of small size studies and to indicate more new prognostic factors, as our group published these years (44,45).

Heterogeneity is a significant problem that can influence the result of meta-analysis. Therefore, to avoid selection biases, we carried a methodological assessment as we implemented in prior studies (44,45). There was no obvious difference between the 10 eligible studies. However, it was hard to perform credible statistical comparisons with a limited study number of each subgroup.

Several limitations of our meta-analysis need to be taken into account while discussing our results. Primarily, potential confounding factors would not be corrected for the reason of the unavailable individual patient data such as age, gender or TNM. Such a literature-based analysis was unlikely to gain adequate information. Secondly, publication bias, selection bias, difference in lab method of detecting SAA and definition of SAA (+) between each study, and method of extrapolation of OR, were also factors that would directly influence our result.

In conclusion, our meta-analysis indicates that high SAA
Figure 3 Forrest plot of ORs stratified on cancer type for the association of SAA expression with 3-year overall survival (OS). SAA, serum amyloid A protein.

Figure 4 Forrest plot of ORs stratified on cancer type for the association of SAA expression with 5-year overall survival (OS). SAA, serum amyloid A protein.
status is correlated with an unfavorable OS in different cancers, especially in RCC, and digestive cancer. Our present and prior results from meta-analyses serve to carry out a prospective multivariate trial aiming to observe which combination of classical and new prognostic biomarkers or which biomarkers will play a more important role in the prognosis of cancer patients.

Acknowledgments

Funding: This work was funded by National Natural Science Foundation of China (No. 81971363). The funding source had no involvement in study design, writing of the report or decision to submit the article for publication.

References


Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.

Footnote

Reporting Checklist: The authors have completed the PRISMA reporting checklist. Available at http://dx.doi.org/10.21037/tcr-20-3417

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/tcr-20-3417). The authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Figure 5 Funnel plot of ORs for stratified on cancer type the association of SAA expression with 3-year overall survival (OS). SAA, serum amyloid A protein.


